Intellectual Property and Technology Commercialization


The Intellectual Property & Technology Commercialization program embodies the spirit of the National Jewish Health brand promise, Science Transforming Life®. We accelerate the development of basic scientific research towards clinical application by identifying and protecting the Center's intellectual property and facilitating business partnerships for technology development, licensing, and commercialization. National Jewish Health has close to 150 technologies in its active portfolio and owns 55 active issued U.S. patents plus additional corresponding foreign patents.

National Jewish Health currently has in its portfolio:

  • 110 active technologies developed from our research
  • 79 active US patents protecting these technologies
  • 50 percent of those active US patents are licensed to biotechnology companies for the development of therapeutics consistent with the spirit of the National Jewish Health brand promise, Science Transforming Life®.

Additionally, in the 10 years since the Intellectual Property & Technology Commercialization program was created, National Jewish Health has:

  • executed 170 license agreements, of which 96 are still active;
  • executed a total of 1317 material transfer agreements; and
  • helped create 8 start-up companies.

Our Technologies

FEATURED TECHNOLOGY: Method To Prevent Biofilm Formation on Contact Lenses and in Wounds

To browse a list of the technologies ready for licensing or further development, select one of the following:


Additional Services 

The Intellectual Property and Technology Commercialization Program is also responsible for:

  • Licensing non-patented biological materials developed in National Jewish Health laboratories
  • Review, negotiation, and approval of Materials Transfer Agreements
  • Approval for use of National Jewish Health copyrighted materials
  • Management and licensing, where appropriate, of National Jewish Health trademarks and copyrights


Transforming Our Discoveries into Therapeutics

 Akela Pharma Logo

Akela Pharma is currently conducting Phase IIb trials of a National Jewish Health developed technology, CGRP. CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilator, bronchoprotector and anti-inflammatory properties.

 Aeolus Logo

Aeolus Pharmaceuticals is developing AEOL 10150, a small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species. AEOL 10150 is currently undergoing human clinical evaluation in patients with ALS. James Crapo, MD, and Brian Day, PhD, of National Jewish Health are inventors on the intellectual property underlying this discovery.

 Juvaris Logo

Juvaris BioTherapeutics was founded in 2003, based on the intellectual property developed at National Jewish Health by Steven Dow, DVM, PhD. Juvaris BioTherapeutics is developing therapeutic vaccines for cancer and infectious diseases using its novel technology platform of cationic lipids and non-coding DNA complexes.

 Innate Pharma Logo

Innate Pharma licensed intellectual property developed by Willi Born, PhD, and Erwin Gelfand, MD, relating to the use of compounds stimulating gamma delta T cells in the treatment of certain respiratory diseases. These compounds are currently in preclinical testing. Innate Pharma SA is a French biopharmaceutical company developing first-in-class drugs targeting the innate immune system.

 Taiga Biotechnologies Logo

Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Their three-pronged approach combines novel breakthroughs by Yosef Refaeli, PhD, John Cambier, PhD, and colleagues at National Jewish Health and University of Colorado Denver in cellular, biologic and small molecule approaches to treat and manage these diseases.

 Taligen Therapeutics Logo

Taligen Therapeutics, Inc., which was founded in March 2004 by Drs. Woody Emlen and V. Michael Holers, is working to develop and commercialize technologies created by scientists from National Jewish Health (Erwin Gelfand, MD) and the University of Colorado Denver. Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The Company employs novel technologies designed to modulate and regulate activation of the complement system.

 VistaGen Logo

VistaGen applies their innovative in vitro embryonic stem (ES) cell technologies to discover and develop new generation drugs and protein biologics, both internally and through strategic collaborations with the pharmaceutical and biotechnology industries. Vistagen's clinically predictive in vitro embryonic stem cell technologies are based on intellectual property developed at National Jewish Health by Gordon Keller, PhD.



Emmanuel Hilaire, PhD
Interim Manager
Phone: 303-398-1262

Stephanie Piersma
Program Administrator
Phone: 303-398-1045
[email protected]

Rizwan Manzer, MD, MBA
Phone: 303-398-1182
[email protected]

Contact Information
National Jewish Health
Intellectual Property and Technology Commercialization
1400 Jackson St., M206
Denver, CO 80206
Fax: 303-270-2352



Our Researchers

Known for "translating" the lessons of basic science and applying them to human diseases, National Jewish Health attracts world-class researchers who conduct leading-edge scientific investigations.

Find a researcher by name.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our A-Z directory of Faculty by Area of Research.